|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Novello S, Barlesi F, Califano R, Cufer T,
Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, et al:
Metastatic non-small-cell lung cancer: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27
suppl 5:v1–v27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Crinò L, Weder W, van Meerbeeck J and
Felip E; ESMO Guidelines Working Group, : Early stage and locally
advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 21 Suppl 5:v103–v115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shi Y, Au JS, Thongprasert S, Srinivasan
S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: A
prospective, molecular epidemiology study of EGFR mutations in
Asian patients with advanced non-small-cell lung cancer of
adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schuette WH, Gröschel A, Sebastian M,
Andreas S, Müller T, Schneller F, Guetz S, Eschbach C, Bohnet S,
Leschinger MI and Reck M: A randomized phase II study of pemetrexed
in combination with cisplatin or carboplatin as first-line therapy
for patients with locally advanced or metastatic non-small-cell
lung cancer. Clin Lung Cancer. 14:215–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fennell DA, Summers Y, Cadranel J, Benepal
T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C and Ferry
D: Cisplatin in the modern era: The backbone of first-line
chemotherapy for non-small cell lung cancer. Cancer Treat Rev.
44:42–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lo Iacono M, Monica V, Vavalà T, Gisabella
M, Saviozzi S, Bracco E, Novello S, Papotti M and Scagliotti GV:
ATF2 contributes to cisplatin resistance in non-small cell lung
cancer and celastrol induces cisplatin resensitization through
inhibition of JNK/ATF2 pathway. Int J Cancer. 136:2598–2609. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang F, Duan S, Tsai Y, Keng PC and Chen
Y, Lee SO and Chen Y: Cisplatin treatment increases stemness
through upregulation of hypoxia-inducible factors by interleukin-6
in non-small cell lung cancer. Cancer Sci. 107:746–754. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Al-Hadiya BM: Niclosamide: Comprehensive
profile. Profiles Drug Subst Excip Relat Methodol. 32:67–96. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Al-Gareeb AI, Aljubory KD and Alkuraishy
HM: Niclosamide as an anti-obesity drug: An experimental study. Eat
Weight Disord. 22:339–344. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chowdhury MK, Turner N, Bentley NL, Das A,
Wu LE, Richani D, Bustamante S, Gilchrist RB, Morris MJ, Shepherd
PR and Smith GC: Niclosamide reduces glucagon sensitivity via
hepatic PKA inhibition in obese mice: Implications for glucose
metabolism improvements in type 2 diabetes. Sci Rep. 7:401592017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang L, Yang M, Yuan Y, Li X and Kuang E:
Niclosamide inhibits lytic replication of Epstein-Barr virus by
disrupting mTOR activation. Antiviral Res. 138:68–78. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang YM, Lu JW, Lin CC, Chin YF, Wu TY,
Lin LI, Lai ZZ, Kuo SC and Ho YJ: Antiviral activities of
niclosamide and nitazoxanide against chikungunya virus entry and
transmission. Antiviral Res. 135:81–90. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Morin F, Kavian N, Nicco C, Cerles O,
Chéreau C and Batteux F: Niclosamide prevents systemic sclerosis in
a reactive oxygen species-induced mouse model. J Immunol.
197:3018–3028. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Y, Li PK, Roberts MJ, Arend RC, Samant
RS and Buchsbaum DJ: Multi-targeted therapy of cancer by
niclosamide: A new application for an old drug. Cancer Lett.
349:8–14. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li R, Hu Z, Sun SY, Chen ZG, Owonikoko TK,
Sica GL, Ramalingam SS, Curran WJ, Khuri FR and Deng X: Niclosamide
overcomes acquired resistance to erlotinib through suppression of
STAT3 in non-small cell lung cancer. Mol Cancer Ther. 12:2200–2212.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu J, Chen X, Ward T, Pegram M and Shen
K: Combined niclosamide with cisplatin inhibits
epithelial-mesenchymal transition and tumor growth in
cisplatin-resistant triple-negative breast cancer. Tumour Biol.
37:9825–9835. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Klimaszewska-Wisniewska A,
Halas-Wisniewska M, Tadrowski T, Gagat M, Grzanka D and Grzanka A:
Paclitaxel and the dietary flavonoid fisetin: A synergistic
combination that induces mitotic catastrophe and autophagic cell
death in A549 non-small cell lung cancer cells. Cancer Cell Int.
16:102016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kang MH, Moon SU, Sung JH, Kim JW, Lee KW,
Lee HS, Lee JS and Kim JH: Antitumor activity of HM781-36B, alone
or in combination with chemotherapeutic agents, in colorectal
cancer cells. Cancer Res Treat. 48:355–364. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang W, Zhou H, Yu Y, Li J, Li H, Jiang
D, Chen Z, Yang D, Xu Z and Yu Z: Combination of gambogic acid with
cisplatin enhances the antitumor effects on cisplatin-resistant
lung cancer cells by downregulating MRP2 and LRP expression. Onco
Targets Ther. 9:3359–3368. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Galluzzi L, Vitale I, Michels J, Brenner
C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems
biology of cisplatin resistance: Past, present and future. Cell
Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tessari M, Pilla M, Andreoli M, Hutcheson
DM and Heidbreder CA: Antagonism at metabotropic glutamate 5
receptors inhibits nicotine- and cocaine-taking behaviours and
prevents nicotine-triggered relapse to nicotine-seeking. Eur J
Pharmacol. 499:121–133. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chong CR and Sullivan DJ Jr: New uses for
old drugs. Nature. 448:645–646. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Osada T, Chen M, Yang XY, Spasojevic I,
Vandeusen JB, Hsu D, Clary BM, Clay TM, Chen W, Morse MA and Lyerly
HK: Antihelminth compound niclosamide downregulatesWnt signaling
and elicits antitumor responses in tumors with activating APC
mutations. Cancer Res. 71:4172–4182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jin Y, Lu Z, Ding K, Li J, Du X, Chen C,
Sun X, Wu Y, Zhou J and Pan J: Antineoplastic mechanisms of
niclosamide in acute myelogenous leukemia stem cells: Inactivation
of the NF-kappaB pathway and generation of reactive oxygen species.
Cancer Res. 70:2516–2527. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li R, You S, Hu Z, Chen ZG, Sica GL, Khuri
FR, Curran WJ, Shin DM and Deng X: Inhibition of STAT3 by
niclosamide synergizes with erlotinib against head and neck cancer.
PLos One. 8:e746702013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scheffer GL, Wijngaard PL, Flens MJ,
Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC and
Scheper RJ: The drug resistance-related protein LRP is the human
major vault protein. Nat Med. 1:578–582. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Filipits M, Pohl G, Stranzl T, Suchomel
RW, Scheper RJ, Jäger U, Geissler K, Lechner K and Pirker R:
Expression of the lung resistance protein predicts poor outcome in
de novo acute myeloid leukemia. Blood. 91:1508–1513.
1998.PubMed/NCBI
|
|
29
|
Dalton WS and Scheper RJ: Lung
resistance-related protein: Determining its role in multidrug
resistance. J Natl Cancer Inst. 91:1604–1605. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kerr EH, Frederick PJ, Egger ME, Stockard
CR, Sellers J, DellaManna D, Oelschlager DK, Amm HM, Eltoum IE,
Straughn JM, et al: Lung resistance-related protein (LRP)
expression in malignant ascitic cells as a prognostic marker for
advanced ovarian serous carcinoma. Ann Surg Oncol. 20:3059–3065.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tsuji K, Wang YH, Takanashi M, Odajima T,
Lee GA, Sugimori H and Motoji T: Overexpression of lung
resistance-related protein and P-glycoprotein and response to
induction chemotherapy in acute myelogenous leukemia. Hematol Rep.
4:e182012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li J, Li ZN, Du YJ, Li XQ, Bao QL and Chen
P: Expression of MRP1, BCRP, LRP, and ERCC1 in advanced
non-small-cell lung cancer: Correlation with response to
chemotherapy and survival. Clin Lung Cancer. 10:414–421. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li J, Li ZN, Yu LC, Bao QL, Wu JR, Shi SB
and Li XQ: Association of expression of MRP1, BCRP, LRP and ERCC1
with outcome of patients with locally advanced non-small cell lung
cancer who received neoadjuvant chemotherapy. Lung Cancer.
69:116–122. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang W, Mao Y, Zhan Y, Huang J, Wang X,
Luo P, Li LI, Mo D, Liu Q, Xu H and Huang C: Prognostic
implications of survivin and lung resistance protein in advanced
non-small cell lung cancer treated with platinum-based
chemotherapy. Oncol Lett. 11:723–730. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Biliran H Jr, Banerjee S, Thakur A, Sarkar
FH, Bollig A, Ahmed F, Wu J, Sun Y and Liao JD: c-Myc-induced
chemosensitization is mediated by suppression of cyclin D1
expression and nuclear factor-kappa B activity in pancreatic cancer
cells. Clin Cancer Res. 13:2811–2821. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Torigoe T, Izumi H, Ishiguchi H, Yoshida
Y, Tanabe M, Yoshida T, Igarashi T, Niina I, Wakasugi T, Imaizumi
T, et al: Cisplatin resistance and transcription factors. Curr Med
Chem Anticancer Agents. 5:15–27. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Reyes-González JM, Armaiz-Peña GN, Mangala
LS, Valiyeva F, Ivan C, Pradeep S, Echevarría-Vargas IM,
Rivera-Reyes A, Sood AK and Vivas-Mejía PE: Targeting c-MYC in
platinum-resistant ovarian cancer. Mol Cancer Ther. 14:2260–2269.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xie C, Pan Y, Hao F, Gao Y, Liu Z, Zhang
X, Xie L, Jiang G, Li Q and Wang E: C-Myc participates in
β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma
cells. APMIS. 122:1251–1258. 2014. View Article : Google Scholar : PubMed/NCBI
|
